<DOC>
	<DOCNO>NCT01622777</DOCNO>
	<brief_summary>To evaluate impact oral rosuvastatin diabetic polyneuropathy , role lipid peroxidation nerve growth factor .</brief_summary>
	<brief_title>The Effect Rosuvastatin Diabetic Polyneuropathy : A Phase IIa Randomized Double-blind Placebo-controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Patients type 2 diabetes mellitus Glycated hemoglobin &lt; 12.0 % Signing informed consent Presence abnormality nerve conduction study Symptoms sign diabetic polyneuropathy Pregnancy lactation Foot ulcer Treatment statins Antioxidant drug and/or supplement one month previous enrolment Inability mobilize Renal and/or hepatic failure</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Rosuvastatin</keyword>
	<keyword>Diabetic polyneuropathy</keyword>
	<keyword>Nerve conduction</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Nerve growth factor</keyword>
</DOC>